AI assistant
Gossamer Bio, Inc. — Director's Dealing 2021
Jun 23, 2021
32603_dirs_2021-06-22_f3de6f54-d139-460e-a61d-fb45b51f7eac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Gossamer Bio, Inc. (GOSS)
CIK: 0001728117
Period of Report: 2021-06-21
Reporting Person: Aranda Richard (Chief Medical Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 204809 | Direct |
| Common Stock | 2539 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $10.71 | 2028-12-10 | Common Stock (38666.0) | Direct | |
| Stock Option (Right to Buy) | $22.1 | 2029-03-25 | Common Stock (45000.0) | Direct | |
| Stock Option (Right to Buy) | $16.4 | 2029-12-23 | Common Stock (13750.0) | Direct | |
| Stock Option (Right to Buy) | $14.55 | 2030-02-14 | Common Stock (34175.0) | Direct | |
| Stock Option (Right to Buy) | $9.79 | 2031-02-25 | Common Stock (60000.0) | Direct |
Footnotes
F1: Includes 13,838 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Also includes 65,247 restricted stock units, which shares will vest in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.
F2: 24,180 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on July 10, 2021 and the last day of each one-month period thereafter through December 10, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F3: 24,375 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on June 25, 2021 and the last day of each one-month period thereafter through March 25, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F4: 4,869 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on June 23, 2021 and the last day of each one-month period thereafter through December 23, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F5: 11,391 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on July 14, 2021 and the last day of each one-month period thereafter through February 14, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F6: 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.